Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.87), $0.01 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $198 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Jefferies sees a buying opportunity in this S&P 500 sector
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance